The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Proleukin trial impacted by pandemic. Forecast sluggish growth 1H 2021. In the absence of a bid for the Company then yeh, unwise to anticipate any significant increase in SP in the short term but hey, AIM is a volatile beast
Iām comfortable holding and looking forward to cash generating Proleukin news in 2021 and the promised accelerated growth in 2022.
Solid results, but not much to excite... nothing new really. I think I'm going to sit on the side & watch for the next 12-18 months, but i can't see it breaking out of the 5-7 range without something like a takeover bid... funny how the market values a business isn't it? Next post a result of -94% profit and the share price rises 4%... this lot post +20% profit, and the share price droops like last weeks celery! I think this one will start to agitate in the 12-18 month timescale... Happy to be proved wrong, and i'll hold for now & topup on any weakness
Seems to me that Proleukin renewal is key to any SP growth.....per their presentation this would result in exceeding the top end of 10% EBITDA growth.
Roll on news from Iovance.
agreed, the dividend is ridiculously tiny, and almost pointless, waste not reducing the debt this time around.
especially as they have managed to push a profit through a good chunk of the covid lockdown, no doubt as they said thanks due to their workers (i have no doubt the execs all hid at home!)
but again, company making good progress while many others are folding, and the share price.... yeah no where near where they think they are worth, that speaks volumes and tells you where the market rates this at
14% increase in full year dividend. Nice but I would have preferred to have seen a reduction in debt instead.
Organic growth forecast to continue then, and and any positive Proleukin news will really fire the burners
EPS up 20%
Net debt to increase 1 H 2021
Organic growth forecast at lower end of 5% - 10% range 2021 with accelerated growth 2022. Well, I reckon 5% growth seen against the backdrop of Covid would be on the wish list of most businneses